Virus–Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Seymour LW, Fisher KD. Oncolytic viruses: finally delivering. Br J Cancer. 2016;114(4):357–361. doi:10.1038/bjc.2015.48126766734
   PubMed Web of Science ®Google Scholar
• Komarova NL, Wodarz D. ODE models for oncolytic virus dynamics. J Theor Biol. 2010;263(4):530–543. doi:10.1016/j.jtbi.2010.01.00920085772
   PubMed Web of Science ®Google Scholar
• Sinkovics JG, Horvath JC. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp (Warsz). 2008;56(S1):1–59. doi:10.1007/s00005-008-0047-918250975
   PubMed Web of Science ®Google Scholar
• Southam CM, Moore AE. Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer. 1952;5(5):1025–1034. doi:10.1002/(ISSN)1097-014212988191
   PubMed Web of Science ®Google Scholar
• Georgiades J, Zielinski T, Cicholska A, Jordan E. Research on the oncolytic effect of APC viruses in cancer of the cervix uteri; preliminary report. Biul Inst Med Morsk Gdansk. 1959;10:49–57.13827367
   PubMedGoogle Scholar
• Lorence RM, Roberts MS, Groene WS, Rabin H. Replication-competent, oncolytic newcastle disease virus for cancer therapy. Monogr Virol. 2001;22:160–182.
   Google Scholar
• Csatary LK, Eckhardt S, Bukosza I, et al. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev. 1993;17(6):619–627.8275514
   PubMedGoogle Scholar
• Asada T. Treatment of human cancer with mumps virus. Cancer. 1974;34(6):1907–1928. doi:10.1002/(ISSN)1097-01424611607
   PubMed Web of Science ®Google Scholar
• Peters C, Grandi P, Nigim F. Updates on oncolytic virus immunotherapy for cancers. Mol Ther Oncolytics. 2019;12:259–262. doi:10.1016/j.omto.2019.01.008
   PubMed Web of Science ®Google Scholar
• Hu JCC, Coffin RS, Davis CJ, et al. A Phase I Study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737. doi:10.1158/1078-0432.CCR-06-075917121894
   PubMed Web of Science ®Google Scholar
• Greig SL. Talimogene laherparepvec: first global approval. Drugs. 2016;76(1):147–154. doi:10.1007/s40265-015-0522-726620366
   PubMed Web of Science ®Google Scholar
• Garber K. China approves world’s first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006;98(5):298–300. doi:10.1093/jnci/djj11116507823
   PubMedGoogle Scholar
• Alberts P, Tilgase A, Rasa A, Bandere K, Venskus D. The advent of oncolytic virotherapy in oncology: the Rigvir(R) story. Eur J Pharmacol. 2018;837:117–126. doi:10.1016/j.ejphar.2018.08.04230179611
   PubMed Web of Science ®Google Scholar
• Babiker HM, Riaz IB, Husnain M, Borad MJ. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. Oncolytic Virother. 2017;6:11–18. doi:10.2147/OV.S10007228224120
   PubMed Web of Science ®Google Scholar
• Bradley S, Jakes AD, Harrington K, Pandha H, Melcher A, Errington-Mais F. Applications of coxsackievirus A21 in oncology. Oncolytic Virother. 2014;3:47–55. doi:10.2147/OV.S5632227512662
   PubMedGoogle Scholar
• Miles LA, Burga LN, Gardner EE, Bostina M, Poirier JT, Rudin CM. Anthrax toxin receptor 1 is the cellular receptor for seneca valley virus. J Clin Invest. 2017;127(8):2957–2967. doi:10.1172/JCI9347228650343
   PubMed Web of Science ®Google Scholar
• Angelova AL, Aprahamian M, Balboni G, et al. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: in vitro and in vivo studies. Mol Ther. 2009;17(7):1164–1172. doi:10.1038/mt.2009.7819367260
   PubMed Web of Science ®Google Scholar
• Desjardins A, Sampson J, Peters K, et al. Final results of a Phase 1 trial of an oncolytic Polio/Rhinovirus Recombinant (Pvsripo) against Recurrent Glioblastoma (Gbm). Neuro-Oncology. 2014;16(suppl 5):v13–v13.
   Web of Science ®Google Scholar
• Zhang Q, Liang C, Yu YA, Chen N, Dandekar T, Szalay AA. The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol Genet Genomics. 2009;282(4):417–435. doi:10.1007/s00438-009-0475-119701652
   PubMed Web of Science ®Google Scholar
• Di Giovine P, Settembre EC, Bhargava AK, et al. Structure of herpes simplex virus glycoprotein d bound to the human receptor nectin-1. PLoS Pathog. 2011;7(9):e1002277. doi:10.1371/journal.ppat.100227721980294
   PubMed Web of Science ®Google Scholar
• Finkelshtein D, Werman A, Novick D, Barak S, Rubinstein M. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci USA. 2013;110(18):7306. doi:10.1073/pnas.121444111023589850
   PubMed Web of Science ®Google Scholar
• Carter GC, Law M, Hollinshead M, Smith GL. Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans. J Gen Virol. 2005;86(5):1279–1290. doi:10.1099/vir.0.80831-015831938
   PubMed Web of Science ®Google Scholar
• Jhawar SR, Thandoni A, Bommareddy PK, et al. Oncolytic viruses-natural and genetically engineered cancer immunotherapies. Front Oncol. 2017;7:202. doi:10.3389/fonc.2017.0020228955655
   PubMed Web of Science ®Google Scholar
• Mansour M, Palese P, Zamarin D. Oncolytic specificity of newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol. 2011;85(12):6015. doi:10.1128/JVI.01537-1021471241
   PubMed Web of Science ®Google Scholar
• Strong JE, Coffey MC, Tang D, Sabinin P, Lee PWK. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 1998;17(12):3351. doi:10.1093/emboj/17.12.33519628872
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642. doi:10.1038/nrd466326323545
   PubMed Web of Science ®Google Scholar
• Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14:559. doi:10.1038/nrc377024990523
   PubMed Web of Science ®Google Scholar
• Kepp O, Galluzzi L, Martins I, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 2011;30(1):61–69. doi:10.1007/s10555-011-9273-421249425
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–2788. doi:10.1200/JCO.2014.58.337726014293
   PubMed Web of Science ®Google Scholar
• Puzanov I, Milhem MM, Minor D, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34(22):2619–2626. doi:10.1200/JCO.2016.67.152927298410
   PubMed Web of Science ®Google Scholar
• Park B-H, Hwang T, Liu T-C, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008;9(6):533–542. doi:10.1016/S1470-2045(08)70107-418495536
   PubMed Web of Science ®Google Scholar
• Noonan AM, Farren MR, Geyer SM, et al. Randomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma. Mol Ther. 2016;24(6):1150–1158. doi:10.1038/mt.2016.6627039845
   PubMed Web of Science ®Google Scholar
• Guo ZS, Liu Z, Kowalsky S, et al. Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives. Front Immunol. 2017;8:555. doi:10.3389/fimmu.2017.0055528555136
   PubMed Web of Science ®Google Scholar
• Marelli G, Howells A, Lemoine NR, Wang Y. Oncolytic viral therapy and the immune system: a double-edged sword against cancer. Front Immunol. 2018;9:866. doi:10.3389/fimmu.2018.0086629755464
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Curti B, Hallmeyer S, et al. Phase II CALM extension study: enhanced immune-cell infiltration within the tumour micro-environment of patients with advanced melanoma following intralesional delivery of Coxsackievirus A21. Eur J Cancer. 2015;51:S677–S677. doi:10.1016/S0959-8049(16)31854-8
   Web of Science ®Google Scholar
• Silk AW, Kaufman H, Gabrail N, et al. Abstract CT026: phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: interim results of the CAPRA clinical trial. Cancer Res. 2017;77(13 Supplement):CT026.
   Web of Science ®Google Scholar
• Andtbacka RHI, Curti BD, Hallmeyer S, et al. Phase II calm extension study: coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment. J ImmunoTher Cancer. 2015;3(Suppl 2):P343. doi:10.1186/2051-1426-3-S2-P343
   Google Scholar
• Zhang Z, Zou W, Wang J, et al. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1. Mol Ther. 2005;11(4):553–562. doi:10.1016/j.ymthe.2004.12.01515771958
   PubMed Web of Science ®Google Scholar
• Gholami S, Marano A, Chen NG, et al. A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer. Breast Cancer Res Treat. 2014;148(3):489–499. doi:10.1007/s10549-014-3180-725391896
   PubMed Web of Science ®Google Scholar
• Kohlhapp FJ, Kaufman HL. Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res. 2016;22(5):1048. doi:10.1158/1078-0432.CCR-15-266726719429
   PubMed Web of Science ®Google Scholar
• Conry RM, Westbrook B, McKee S, Norwood TG. Talimogene laherparepvec: first in class oncolytic virotherapy. Hum Vaccin Immunother. 2018;14(4):839–846. doi:10.1080/21645515.2017.141289629420123
   PubMed Web of Science ®Google Scholar
• Cox RM, Plemper RK. Structure and organization of paramyxovirus particles. Curr Opin Virol. 2017;24:105–114. doi:10.1016/j.coviro.2017.05.00428601688
   PubMed Web of Science ®Google Scholar
• Wodarz D, Hofacre A, Lau JW, Sun Z, Fan H, Komarova NL. Complex spatial dynamics of oncolytic viruses in vitro: mathematical and experimental approaches. PLoS Comput Biol. 2012;8(6):e1002547. doi:10.1371/journal.pcbi.100254722719239
   PubMed Web of Science ®Google Scholar
• Wodarz D. Use of oncolytic viruses for the eradication of drug-resistant cancer cells. J R Soc Interface. 2009;6(31):179–186. doi:10.1098/rsif.2008.019118664430
   PubMed Web of Science ®Google Scholar
• Duffy S. Why are RNA virus mutation rates so damn high? PLoS Biol. 2018;16(8):e3000003. doi:10.1371/journal.pbio.300000330102691
   PubMed Web of Science ®Google Scholar
• Helenius A. Virus entry: looking back and moving forward. J Mol Biol. 2018;430(13):1853–1862. doi:10.1016/j.jmb.2018.03.03429709571
   PubMed Web of Science ®Google Scholar
• Kumar CS, Dey D, Ghosh S, Banerjee M. Breach: host membrane penetration and entry by nonenveloped viruses. Trends Microbiol. 2018;26(6):525–537. doi:10.1016/j.tim.2017.09.01029079499
   PubMed Web of Science ®Google Scholar
• Jolly CL, Sattentau QJ. Attachment factors In: Pöhlmann S, Simmons G, editors. Viral Entry into Host Cells. New York: Springer New York; 2013:1–23.
   Google Scholar
• Vähä-Koskela M, Hinkkanen A. Tumor restrictions to oncolytic virus. Biomedicines. 2014;2(2):163–194. doi:10.3390/biomedicines202016328548066
   PubMedGoogle Scholar
• McCarthy C, Jayawardena N, Burga LN, Bostina M. Developing picornaviruses for cancer therapy. Cancers. 2019;11(5):685. doi:10.3390/cancers11050685
   Web of Science ®Google Scholar
• Bostina M. Monoclonal antibodies point to achilles’ heel in picornavirus capsid. PLoS Biol. 2019;17(4):e3000232. doi:10.1371/journal.pbio.300023230995226
   PubMed Web of Science ®Google Scholar
• Howells A, Marelli G, Lemoine NR, Wang Y. Oncolytic viruses-interaction of virus and tumor cells in the battle to eliminate cancer. Front Oncol. 2017;7:195. doi:10.3389/fonc.2017.0019528944214
   PubMed Web of Science ®Google Scholar
• He Y, Mueller S, Chipman PR, et al. Complexes of Poliovirus serotypes with their common cellular receptor, CD155. J Virol. 2003;77(8):4827. doi:10.1128/JVI.77.8.4827-4835.200312663789
   PubMed Web of Science ®Google Scholar
• Anderson BD, Nakamura T, Russell SJ, Peng K-W. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004;64(14):4919. doi:10.1158/0008-5472.CAN-04-088415256464
   PubMed Web of Science ®Google Scholar
• Bergelson JM, Shepley MP, Chan BM, Hemler ME, Finberg RW. Identification of the integrin VLA-2 as a receptor for echovirus 1. Science. 1992;255(5052):1718–1720. doi:10.1126/science.15535611553561
   PubMed Web of Science ®Google Scholar
• Yu Z, Adusumilli PS, Eisenberg DP, et al. Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol Ther. 2007;15(1):103–113. doi:10.1038/sj.mt.630000917164781
   PubMed Web of Science ®Google Scholar
• Carfí A, Willis SH, Whitbeck JC, et al. Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol Cell. 2001;8(1):169–179. doi:10.1016/S1097-2765(01)00298-211511370
   PubMed Web of Science ®Google Scholar
• Xiao C, Bator-Kelly CM, Rieder E, et al. The crystal structure of Coxsackievirus A21 and its interaction with ICAM-1. Structure. 2005;13(7):1019–1033. doi:10.1016/j.str.2005.04.01116004874
   PubMed Web of Science ®Google Scholar
• Yoder JD, Cifuente JO, Pan J, Bergelson JM, Hafenstein S. The crystal structure of a Coxsackievirus B3-RD variant and a refined 9-angstrom cryo-electron microscopy reconstruction of the virus complexed with Decay-Accelerating Factor (DAF) Provide a new footprint of DAF on the virus surface. J Virol. 2012;86(23):12571. doi:10.1128/JVI.01592-1222973031
   PubMed Web of Science ®Google Scholar
• Rea VEA, Rossi FW, Paulis AD, Ragno P, Selleri C, Montuori N. 67 kDa laminin receptor: structure, function and role in cancer and infection. Infez Med. 2012;20(Suppl 2):8–12.
   PubMedGoogle Scholar
• Gong J, Mita MM. Activated Ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells. Front Oncol. 2014;4:167. doi:10.3389/fonc.2014.0016725019061
   PubMedGoogle Scholar
• Norman KL, Hirasawa K, Yang A-D, Shields MA, Lee PWK. Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A. 2004;101(30):11099. doi:10.1073/pnas.040431010115263068
   PubMed Web of Science ®Google Scholar
• Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4(4):263–275. doi:10.1016/S1535-6108(03)00241-114585354
   PubMed Web of Science ®Google Scholar
• Morizono K, Xie Y, Ringpis G-E, et al. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med. 2005;11:346. doi:10.1038/nm119215711560
   PubMed Web of Science ®Google Scholar
• Muik A, Stubbert LJ, Jahedi RZ, et al. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency. Cancer Res. 2014;74(13):3567–3578. doi:10.1158/0008-5472.CAN-13-330624812275
   PubMed Web of Science ®Google Scholar
• Nakamura T, Peng K-W, Harvey M, et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol. 2005;23(2):209–214. doi:10.1038/nbt106015685166
   PubMed Web of Science ®Google Scholar
• Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 1998;72(12):9706–9713. doi:10.1128/JVI.72.12.9706-9713.19989811704
   PubMed Web of Science ®Google Scholar
• Nakano K, Asano R, Tsumoto K, et al. Herpes simplex virus targeting to the EGF receptor by a gD-specific soluble bridging molecule. Mol Ther. 2005;11(4):617–626. doi:10.1016/j.ymthe.2004.12.01215771964
   PubMed Web of Science ®Google Scholar
• He B, Gross M, Roizman B. The γ1 34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1α to dephosphorylate the α subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA. 1997;94(3):843.9023344
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet. 2001;357(9267):1513–1518. doi:10.1016/S0140-6736(00)04638-911377626
   PubMed Web of Science ®Google Scholar
• Tomazin R, van Schoot NEG, Goldsmith K, et al. Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP. J Virol. 1998;72(3):2560. doi:10.1128/JVI.72.3.2560-2563.19989499125
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Ruby CE, Hughes T, Slingluff CL. Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma. J ImmunoTher Cancer. 2014;2(1):11. doi:10.1186/2051-1426-2-1124971166
   PubMedGoogle Scholar
• Dix BR, O’Carroll SJ, Myers CJ, Edwards SJ, Braithwaite AW. Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53. Cancer Res. 2000;60(10):2666.10825139
   PubMed Web of Science ®Google Scholar
• Rogulski KR, Freytag SO, Zhang K, et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 2000;60(5):1193.10728673
   PubMed Web of Science ®Google Scholar
• Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6:879. doi:10.1038/7863810932224
   PubMed Web of Science ®Google Scholar
• Martínez-Vélez N, Garcia-Moure M, Marigil M, et al. The oncolytic virus delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun. 2019;10(1):2235. doi:10.1038/s41467-019-10043-031138805
   PubMed Web of Science ®Google Scholar
• McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001;61(24):8751.11751395
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477:99. doi:10.1038/nature1035821886163
   PubMed Web of Science ®Google Scholar
• Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19:329. doi:10.1038/nm.308923396206
   PubMed Web of Science ®Google Scholar
• Heo J, Breitbach CJ, Moon A, et al. Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther. 2011;19(6):1170–1179. doi:10.1038/mt.2011.3921427706
   PubMed Web of Science ®Google Scholar
• Atsumi S, Matsumine A, Toyoda H, et al. Oncolytic virotherapy for human bone and soft tissue sarcomas using live attenuated poliovirus. Int J Oncol. 2012;41(3):893–902. doi:10.3892/ijo.2012.151422692919
   PubMed Web of Science ®Google Scholar
• Ansardi DC, Porter DC, Jackson CA, Gillespie GY, Morrow CD. RNA replicons derived from poliovirus are directly oncolytic for human tumor cells of diverse origins. Cancer Res. 2001;61(23):8470–8479.11731430
   PubMed Web of Science ®Google Scholar
• Toyoda H, Yin J, Mueller S, Wimmer E, Cello J. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res. 2007;67(6):2857–2864. doi:10.1158/0008-5472.CAN-06-371317363609
   PubMed Web of Science ®Google Scholar
• Jahan N, Wimmer E, Mueller S. A host-specific, temperature-sensitive translation defect determines the attenuation phenotype of a human rhinovirus/poliovirus chimera, PV1(RIPO). J Virol. 2011;85(14):7225–7235. doi:10.1128/JVI.01804-0921561914
   PubMed Web of Science ®Google Scholar
• Gromeier M, Alexander L, Wimmer E. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci U S A. 1996;93(6):2370–2375. doi:10.1073/pnas.93.6.23708637880
   PubMed Web of Science ®Google Scholar
• Desjardins A, Gromeier M, Herndon JE 2nd, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379(2):150–161. doi:10.1056/NEJMoa171643529943666
   PubMed Web of Science ®Google Scholar
• Filley AC, Dey M. Immune system, friend or foe of oncolytic virotherapy? Front Oncol. 2017;7:106. doi:10.3389/fonc.2017.0010628589085
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Cunningham C, Tong AW, et al. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther. 2003;10:341. doi:10.1038/sj.cgt.770058512719704
   PubMed Web of Science ®Google Scholar
• Parato KA, Senger D, Forsyth PAJ, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer. 2005;5:965. doi:10.1038/nrc175016294217
   PubMed Web of Science ®Google Scholar
• Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science. 2006;311(5768):1780. doi:10.1126/science.112141116556847
   PubMed Web of Science ®Google Scholar
• Chen Y, Yu D-C, Charlton D, Henderson DR. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum Gene Ther. 2000;11(11):1553–1567. doi:10.1089/1043034005008328910945769
   PubMed Web of Science ®Google Scholar
• White CL, Twigger KR, Vidal L, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (dearing type 3) during a phase I clinical trial. Gene Ther. 2008;15:911. doi:10.1038/gt.2008.2118323793
   PubMed Web of Science ®Google Scholar
• Rudin CM, Poirier JT, Senzer NN, et al. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clin Cancer Res. 2011;17(4):888–895. doi:10.1158/1078-0432.CCR-10-170621304001
   PubMed Web of Science ®Google Scholar
• Tsai V, Johnson DE, Rahman A, et al. Impact of Human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin Cancer Res. 2004;10(21):7199. doi:10.1158/1078-0432.CCR-04-076515534093
   PubMed Web of Science ®Google Scholar
• Sumida SM, Truitt DM, Lemckert AAC, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol. 2005;174(11):7179. doi:10.4049/jimmunol.174.11.717915905562
   PubMed Web of Science ®Google Scholar
• Ferguson MS, Lemoine NR, Wang Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol. 2012;2012:1–14. doi:10.1155/2012/805629
   Google Scholar
• Davies DH, McCausland MM, Valdez C, et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol. 2005;79(18):11724–11733. doi:10.1128/JVI.79.18.11724-11733.200516140750
   PubMed Web of Science ®Google Scholar
• Dietrich MH, Ogden KM, Katen SP, et al. Structural insights into reovirus σ1 interactions with two neutralizing antibodies. J Virol. 2017;91(4):e01621–e01616. doi:10.1128/JVI.01621-1627928010
   PubMed Web of Science ®Google Scholar
• Ong HT, Hasegawa K, Dietz AB, Russell SJ, Peng KW. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther. 2006;14:324. doi:10.1038/sj.gt.330288017051248
   PubMed Web of Science ®Google Scholar
• Dingli D, Peng K-W, Harvey ME, et al. Interaction of measles virus vectors with auger electron emitting radioisotopes. Biochem Biophys Res Commun. 2005;337(1):22–29. doi:10.1016/j.bbrc.2005.08.26116171777
   PubMed Web of Science ®Google Scholar
• Chakradhar S. Viral vanguard: designing cancer-killing viruses to chase metastatic tumors. Nat Med. 2017;23(6):652–655. doi:10.1038/nm0617-65228586331
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658. doi:10.1038/nbt.228722781695
   PubMed Web of Science ®Google Scholar
• Wong HH, Lemoine NR, Wang Y. Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses. 2010;2(1):78–106. doi:10.3390/v201007820543907
   PubMed Web of Science ®Google Scholar
• Sun JY, Anand-Jawa V, Chatterjee S, Wong KK. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther. 2003;10(11):964–976. doi:10.1038/sj.gt.330203912756417
   PubMed Web of Science ®Google Scholar
• Lang SI, Giese NA, Rommelaere J, Dinsart C, Cornelis JJ. Humoral immune responses against minute virus of mice vectors. J Gene Med. 2006;8(9):1141–1150. doi:10.1002/(ISSN)1521-225416800041
   PubMed Web of Science ®Google Scholar
• Tesfay MZ, Kirk AC, Hadac EM, et al. PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice. J Virol. 2013;87(7):3752. doi:10.1128/JVI.02832-1223325695
   PubMed Web of Science ®Google Scholar
• Tesfay MZ, Ammayappan A, Federspiel MJ, et al. Vesiculovirus neutralization by natural IgM and complement. J Virol. 2014;88(11):6148. doi:10.1128/JVI.00074-1424648451
   PubMed Web of Science ®Google Scholar
• Hutzler S, Erbar S, Jabulowsky RA, et al. Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles. Sci Rep. 2017;7(1):16892. doi:10.1038/s41598-017-16928-829203786
   PubMed Web of Science ®Google Scholar
• Ricca JM, Oseledchyk A, Walther T, et al. Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy. Mol Ther. 2018;26(4):1008–1019. doi:10.1016/j.ymthe.2018.01.01929478729
   PubMed Web of Science ®Google Scholar
• Power AT, Wang J, Falls TJ, et al. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther. 2007;15(1):123–130. doi:10.1038/sj.mt.630003917164783
   PubMed Web of Science ®Google Scholar
• Ilett EJ, Bárcena M, Errington-Mais F, et al. Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res. 2011;17(9):2767. doi:10.1158/1078-0432.CCR-10-326621389099
   PubMed Web of Science ®Google Scholar
• Ilett EJ, Prestwich RJ, Kottke T, et al. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene Ther. 2009;16:689. doi:10.1038/gt.2009.2919282847
   PubMed Web of Science ®Google Scholar
• Berkeley RA, Steele LP, Mulder AA, et al. Antibody-neutralized reovirus is effective in oncolytic virotherapy. Cancer Immunol Res. 2018;6(10):1161. doi:10.1158/2326-6066.CIR-18-030930209061
   PubMed Web of Science ®Google Scholar
• Hammer K, Kazcorowski A, Liu L, et al. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells. Int J Cancer. 2015;137(4):978–990. doi:10.1002/ijc.v137.425604186
   PubMed Web of Science ®Google Scholar
• Pereboeva L, Komarova S, Mikheeva G, Krasnykh V, Curiel DT. Approaches to utilize mesenchymal progenitor cells as cellular vehicles. Stem Cells. 2003;21(4):389–404. doi:10.1634/stemcells.21-4-38912832693
   PubMed Web of Science ®Google Scholar
• Shikano T, Kasuya H, Sahin TT, et al. High therapeutic potential for systemic delivery of a liposome-conjugated herpes simplex virus. Curr Cancer Drug Targets. 2011;11(1):111–122. doi:10.2174/15680091179374367321062239
   PubMed Web of Science ®Google Scholar
• Wan Y, Han J, Fan G, Zhang Z, Gong T, Sun X. Enzyme-responsive liposomes modified adenoviral vectors for enhanced tumor cell transduction and reduced immunogenicity. Biomaterials. 2013;34(12):3020–3030. doi:10.1016/j.biomaterials.2012.12.05123360783
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang H, Zou H, et al. Liposome encapsulation of oncolytic virus M1 to reduce immunogenicity and immune clearance in vivo. Mol Pharm. 2019;16(2):779–785. doi:10.1021/acs.molpharmaceut.8b0104630604617
   PubMed Web of Science ®Google Scholar
• Yotnda P, Davis AR, Hicks MJ, Templeton NS, Benner MK. Liposomal enhancement of the antitumor activity of conditionally replication-competent adenoviral plasmids. Mol Ther. 2004;9(4):489–495. doi:10.1016/j.ymthe.2004.01.01815093179
   PubMed Web of Science ®Google Scholar
• Qiao J, Wang H, Kottke T, et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res. 2008;14(1):259. doi:10.1158/1078-0432.CCR-07-151018172278
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Cyclophosphamide, oncolytic virus. Cancer. 2019.
   Google Scholar
• Fontanellas A, Hervás-Stubbs S, Mauleón I, et al. Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates. Mol Ther. 2010;18(4):754–765. doi:10.1038/mt.2009.31220087317
   PubMed Web of Science ®Google Scholar
• Muharemagic D, Zamay A, Ghobadloo SM, et al. Aptamer-facilitated protection of oncolytic virus from neutralizing antibodies. Mole Ther Nucleic Acids. 2014;3(6):e167–e167. doi:10.1038/mtna.2014.19
   Web of Science ®Google Scholar
• Niemann J, Woller N, Brooks J, et al. Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy. Nat Commun. 2019;10(1):3236. doi:10.1038/s41467-019-11137-531324774
   PubMed Web of Science ®Google Scholar
• Xu C, Goß AV, Dorneburg C, Debatin K-M, Wei J, Beltinger C. Proof-of-principle that a decoy virus protects oncolytic measles virus against neutralizing antibodies. Oncolytic Virother. 2018. doi:10.2147/OV.S150637
   Web of Science ®Google Scholar
• Zhang Z, Krimmel J, Zhang Z, Hu Z, Seth P. Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model. Hum Gene Ther. 2011;22(9):1137–1142. doi:10.1089/hum.2011.00321480822
   PubMed Web of Science ®Google Scholar
• Ichihashi Y. Extracellular enveloped vaccinia virus escapes neutralization. Virology. 1996;217(2):478–485. doi:10.1006/viro.1996.01428610439
   PubMed Web of Science ®Google Scholar
• Kirn DH, Wang Y, Liang W, Contag CH, Thorne SH. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res. 2008;68(7):2071. doi:10.1158/0008-5472.CAN-07-651518381410
   PubMed Web of Science ®Google Scholar
• Lech PJ, Tobin GJ, Bushnell R, et al. Epitope dampening monotypic measles virus hemagglutinin glycoprotein results in resistance to cocktail of monoclonal antibodies. PLoS One. 2013;8(1):e52306. doi:10.1371/journal.pone.005230623300970
   PubMed Web of Science ®Google Scholar
• Iankov ID, Blechacz B, Liu C, et al. Infected Cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther. 2007;15(1):114–122. doi:10.1038/sj.mt.630002017164782
   PubMed Web of Science ®Google Scholar
• Aoyama K, Kuroda S, Morihiro T, et al. Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system. Sci Rep. 2017;7(1):14177. doi:10.1038/s41598-017-14717-x29074882
   PubMed Web of Science ®Google Scholar